Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HLX 10

Next Previous
Drug Profile

HLX 10

Alternative Names: Anti-PD-1 monoclonal antibody-Henlix Biotech; Anti-PD-I mAb-Henlix Biotech; HLX-10; Recombinant humanized anti-PD-1 monoclonal antibody - Henlix Biotech

Latest Information Update: 19 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Henlix Biotech
  • Developer Henlix Biotech; Shanghai Henlius Biotech
  • Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer; Oesophageal cancer; Small cell lung cancer
  • Phase II Liver cancer; Solid tumours
  • Clinical Phase Unknown Hepatitis B

Most Recent Events

  • 05 Nov 2019 Shanghai Henlius Biotech plans a phase II trial for Cervical cancer (Late-stage disease, Second-line therapy or greater, Combination therapy) (IV, Injection), in November 2019 , (NCT04150575)
  • 25 Oct 2019 Shanghai Henlius Biotech plans a phase III trial for Gastric cancer (Neoadjuvant therapy, Adjuvant therapy) in November 2019 (IV) (NCT04139135)
  • 21 Oct 2019 Henlix plans a phase II trial for Hepatitis B (Treatment-experienced) (IV, Injection), in November 2019 (NCT04133259)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top